NDUFS5
ENSG00000168653
Target class
Enzyme
Chromosome
1
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- CI-15k
- Target name
- NDUFS5
- Gene name
- NADH:ubiquinone oxidoreductase subunit S5
- Gene symbol
- NDUFS5
- Protein name
- NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 (Complex I-15 kDa) (CI-15 kDa) (NADH-ubiquinone oxidoreductase 15 kDa subunit)
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 647.36
- Tissue specificity (Gini)
- 0.164
- Tissue specificity (tau)
- 0.381
- KEGG gene identifiers
- hsa:4725
- Protein interaction confidence
- 0.943083
- Protein interaction partners
- 96
- R-HSA-611105
- R-HSA-6799198
- End position
- 39034636
- Start position
- 39026318
- Chromosome
- 1
- Strand
- Forward
- Mitochondrion inner membrane
- Peripheral membrane protein . Mitochondrion intermembrane space .
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.38102
- Expression inequality (Gini)
- 0.164446
Expression in transcripts per million
- Heart - Left Ventricle
- 647.36
- Heart - Atrial Appendage
- 627.26
- Brain - Frontal Cortex (BA9)
- 613.23
- Colon - Sigmoid
- 589.2
- Cells - Cultured fibroblasts
- 560.86
Expression in transcripts per million
- Heart - Left Ventricle647.36
- Heart - Atrial Appendage627.26
- Brain - Frontal Cortex (BA9)613.23
- Colon - Sigmoid589.2
- Cells - Cultured fibroblasts560.86
- Esophagus - Gastroesophageal Junction554.45
- Brain - Anterior cingulate cortex (BA24)548.74
- Esophagus - Muscularis541.17
- Brain - Nucleus accumbens (basal ganglia)516.55
- Muscle - Skeletal513.67
- Artery - Tibial512.04
- Artery - Coronary493.06
- Uterus490.3
- Artery - Aorta483.32
- Cells - EBV-transformed lymphocytes478.56
- Brain - Cerebellar Hemisphere475.38
- Pituitary467.63
- Fallopian Tube467.59
- Ovary466.43
- Brain - Cortex458.56
- Cervix - Ectocervix440.14
- Brain - Caudate (basal ganglia)437.8
- Brain - Hypothalamus428.62
- Brain - Amygdala412.92
- Cervix - Endocervix403.46
And 29 more, listed on the interactive page.
Biological processes
- GO:0032981
- GO:0005739
- GO:0005743
- GO:0045271
Molecular functions
- GO:0005515
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor